
|Articles|April 4, 2016
May 2016 — Therapeutic Innovation & Regulatory Science (TIRS): Focus on Pharmaceutical Compounding
Author(s)DIA
Advertisement
Pharmaceutical compounding is an essential aspect of medicine in the US, although with inherent risks that must be understood and managed. In May 2016, the Special Section of
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
3
How AI Is Transforming Drug Labeling
4
FDA’s Shift Signals a New Era for Data-Driven Drug Development
5




